Seres Therapeutics Inc (NASDAQ:MCRB) – Cantor Fitzgerald raised their FY2018 earnings estimates for shares of Seres Therapeutics in a research report issued to clients and investors on Sunday, Zacks Investment Research reports. Cantor Fitzgerald analyst W. Tanner now forecasts that the biotechnology company will earn ($2.37) per share for the year, up from their prior estimate of ($2.72).
Other equities research analysts have also issued research reports about the company. BidaskClub lowered Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, March 9th. Zacks Investment Research lowered Seres Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 3rd. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $18.00.
Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings data on Thursday, March 8th. The biotechnology company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.02. Seres Therapeutics had a negative return on equity of 103.46% and a negative net margin of 278.44%. The company had revenue of $3.06 million during the quarter, compared to analyst estimates of $3.00 million.
A number of hedge funds have recently bought and sold shares of MCRB. New York State Common Retirement Fund grew its holdings in Seres Therapeutics by 59.6% during the 2nd quarter. New York State Common Retirement Fund now owns 23,300 shares of the biotechnology company’s stock valued at $263,000 after buying an additional 8,699 shares in the last quarter. Northern Trust Corp grew its holdings in Seres Therapeutics by 16.2% during the 2nd quarter. Northern Trust Corp now owns 235,766 shares of the biotechnology company’s stock valued at $2,664,000 after buying an additional 32,875 shares in the last quarter. Vanguard Group Inc. grew its holdings in Seres Therapeutics by 1.2% during the 2nd quarter. Vanguard Group Inc. now owns 1,585,026 shares of the biotechnology company’s stock valued at $17,911,000 after buying an additional 19,363 shares in the last quarter. Ark Investment Management LLC grew its holdings in Seres Therapeutics by 21.5% during the 2nd quarter. Ark Investment Management LLC now owns 765,191 shares of the biotechnology company’s stock valued at $8,647,000 after buying an additional 135,276 shares in the last quarter. Finally, Parametric Portfolio Associates LLC grew its holdings in Seres Therapeutics by 2.7% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 21,915 shares of the biotechnology company’s stock valued at $248,000 after buying an additional 580 shares in the last quarter. 79.02% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Equities Analysts Offer Predictions for Seres Therapeutics Inc’s FY2018 Earnings (MCRB)” was published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://stocknewstimes.com/2018/03/21/fy2018-eps-estimates-for-seres-therapeutics-inc-mcrb-lifted-by-cantor-fitzgerald.html.
About Seres Therapeutics
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.